Miruvor
Sign up
The short answer

What studies of Olmesartan (Benicar) found

1paper on Olmesartan (Benicar)
1study testing Olmesartan (Benicar) alone; we couldn't read how many people
0randomised trials, the strongest kind of study

At a glance, by condition

ME/CFS: C Might help, very uncertain

Based on the strongest evidence, studies with no comparison group (very low certainty), for overall symptoms.

1 outcome rated · see each below

How we got this

Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.

What this means: Olmesartan (Benicar) might help some people with ME/CFS, but research can’t show it yet. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.

Ask about this treatment

Sign up free to read the rest of what studies found.

You’ll see the full picture: how each symptom fared, every grade with its reasons, side effects, the doses studied and all 1 paper.

The grades, in plain words

Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.

  1. A
    HelpsImprovement, high certainty
    Probably helpsImprovement, moderate certainty
  2. B
    May helpImprovement, low certainty
  3. Olmesartan (Benicar) · ME/CFS is hereC
    Might help, very uncertainImprovement, very low certainty
    Mixed resultsStudies disagree
  4. D
    Little or no differenceStudies found little or no difference
  5. F
    HarmsIt made things worse

By symptom and daily life

ME/CFS

Daily life and health overall

Overall symptoms1 study Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people, or how many isn't reported; not all results were tested against chance.

Studies with no comparison group1 study · 40 mg, every 4–8 h (few people)

Overall symptoms improved.

The evidence is very uncertain about the effect of olmesartan (Benicar) on overall symptoms in ME/CFS. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people, or how many isn't reported
  • Not all results were tested against chance
See the 1 study
  1. Immunostimulation in the treatment for chronic fatigue syndrome/myalgic encephalomyelitis. (2013)

    People in the study
    —
    Dose
    40 mg, every 4–8 h
    Outcome
    time to recover
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I

Side effects

Stopping because of side effects1 study
Side effects studies reported1 kind
Side effects studies reported, and how many studies reported each
Side effectStudies that reported it
Worse symptoms or a flare1 study

Doses studied

What researchers used, as the papers print it; not a recommendation.

  1. 1Start

    40 mg at the start

  2. 2Top dose

    Most often 40 mg (1 of 1 studies)

Doses across 1 study

40 to 40 mg.

Each study’s dose, as printed

All papers

A little hope, every Sunday

New recovery stories and data-driven research on ME/CFS and long COVID. Ideas worth considering, and the evidence behind them.

Free · Unsubscribe anytime